Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
145 results about "Hbv replication" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
Owner:JANSSEN SCI IRELAND UC
Application of CRISPR-Cas9 system based on new gRNA (guide ribonucleic acid) sequence in preparing drugs for treating hepatitis B
PendingCN105647922AInhibition of replicationInhibit expressionOrganic active ingredientsVectorsHepatitis B virusHbv replication
The invention discloses a gRNA (guide ribonucleic acid) sequence. The sequence can be used for DNA (deoxyribonucleic acid) sequence edition by using a hepatitis B virus genome S gene conserved region site as a target sequence, can successfully destroy the HBV (hepatitis B virus) cccDNA and integrated-state HBV DNA in a HBV stable cell model and an HBV hydrodynamic mouse model, and obtains obvious effects on inhibiting HBV replication and expression. The invention also discloses application of the CRISPR-Cas9 system containing the gRNA sequence in preparing drugs for treating hepatitis B.
Owner:INST OF PLA FOR DISEASE CONTROL & PREVENTION
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
ActiveUS20130095067A1Symptoms improvedReduce probabilityBiocidePeptide/protein ingredientsMammalHepadnavirus
The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.
Owner:ORYZON GENOMICS SA
Specific sgRNA combined with immunogene to inhibit HBV replication, expression vector thereof, and application of specific sgRNA and expression vector
ActiveCN105821039AImprove targetingHigh knockout efficiencyOrganic active ingredientsGenetic material ingredientsHepatitis B Virus AntigenIn vivo
The invention provides a specific sgRNA combined with an immunogene to inhibit HBV replication, an expression vector thereof, and an application of the specific sgRNA and the expression vector. The sgRNA sequences of a human hepatitis B virogene suitable for CRISPR-Cas9 targeting editing and a PD-1 gene are designed, the plasmid vector of the sgRNA inhibiting HBV and PD-1 genes is constructed, and the plasmid vector and a nuclease gene expression vector are transferred to HBV transgenic mice, and can obviously inhibit HBV DNA replication. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, and high CRISPR-Cas9 knockout efficiency. The sgRNAs specifically targeting the HBV and PD-1 genes can accurately splice the HBV and PD-1 genes, inhibit in vivo hepatitis B virus replication, and reduce the hepatitis B virus antigen expression.
Owner:李旭
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of Formula (I)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of Formula (ID)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, Ra to Rd and R4 to R6 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of Formula (I)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R1, R2, R3 and R4 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1-R5, B and Z have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN INFECTIOUS DISEASES DIAGNOSTICS
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of Formula (I)including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
InactiveUS20070027099A1Reduces HBV viral loadInhibited HBV gene expressionGenetic material ingredientsFermentationHbv replicationViral vector
The invention provides a vector comprising an AAV-shRNA vector. The vector is preferably rAAV-151i / 1694i. The invention also provides a method of suppressing or inhibiting HBV replication in liver cells infected therewith, comprising administering an amount of an AAVB-shRNA vector effective to suppress, inhibit or reduce HBV replication.
Owner:HONG KONG THE UNIV OF
Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of formula (I)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X and R1 to R8 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of Formula (A)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R5 to R6 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
Inhibitors of HBV replication of formula (I)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R1 to R7 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of Formula (I-A)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of formula (I)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R1 to R7 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
InactiveUS20030032596A1Highly specific and efficacious methodImprove efficacyBiocidePeptide/protein ingredientsDiseaseHepatocellular carcinoma
Owner:NEW YORK UNIV MEDICAL CENT
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
Inhibitors of HBV replication of Formula (IA)including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X and R1 to R6 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Owner:JANSSEN SCI IRELAND UC
Therapeutic hepatitis B vaccine
ActiveCN102462840AInhibition of replicationDigestive systemAntiviralsActive componentHepatitis B Surface Antigens
The invention discloses a therapeutic hepatitis B vaccine. Active components of the therapeutic hepatitis B vaccine comprise a protein gp96, a hepatitis B surface antigen and a hepatitis B core protein. The protein gp96 has a sequence shown in the sequence 1 of the sequence table. The hepatitis B surface antigen has a sequence shown in the sequence 5 of the sequence table. The hepatitis B core protein has a sequence shown in the sequence 3 of the sequence table. The active components also comprise a plasmid pcDNA-gp96 containing a coding gene of the protein gp96, a plasmid pcDNA-HB containing a coding gene of the hepatitis B surface antigen and a plasmid pcDNA-HBc containing a coding gene of the hepatitis B core protein. The therapeutic hepatitis B vaccine provided by the invention can effectively inhibit hepatitis B virus (HBV) replication, can eliminate viruses infecting the liver and has a very important value to hepatitis B prevention and treatment.
Owner:北京热休生物技术有限公司
Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B
Owner:JANSSEN SCI IRELAND UC
Application of 4-hydroxy salicylamide in preparing medicament for preventing and treating hepatitis and resisting tumor
ActiveCN102379881AHigh RR enzyme inhibitory activityPrevent proliferationOrganic active ingredientsDigestive systemMyeloid leukemiaChronic myeloid leukaemia
The invention provides novel application of 4-hydroxy salicylamide in the field of pharmacy. The compound is an inhibitor of ribonucleotide reductase (RR), and can achieve the aims of inhibiting replication of HBV and treating hepatitis, in particular the hepatitis B by inhibiting activity of RR enzyme to block synthesis of dNTPs (deoxynucleotide triphosphates) required by hepatitis B virus (HBV)replication, achieve the aim of preventing and treating liver cancer by inhibiting the activity of RR of liver cancer cells, including the RR activity activated by HBV to inhibit proliferation of liver cancer cells, and achieve the aim of treating various tumors by inhibiting the RR. The 4-hydroxy salicylamide can be used for preventing and treating hepatitis B, liver cancer, oropharyngeal epithelioma, colorectal cancer, ovarian cancer, non-small cell lung cancer, chronic myeloid leukemia and other tumors, and has important application prospect.
Owner:ZHEJIANG UNIV +1
Substituted pyrrolizine compounds and uses thereof
ActiveCN109790168AHalogenated hydrocarbon active ingredientsOrganic chemistryPharmaceutical drugHbv replication
This application relates to substituted fused pyrrole compounds of formula I, and pharmaceutical compositions comprising them which inhibit HBV replication, and methods of making and using them (Formula (I)).
Owner:GILEAD SCI INC
Application of interferon-induced transmembrane protein 3 (IFITM 3) for preparing medicament against hepatitis B virus (HBV) infection
The invention relates to new application of interferon-induced transmembrane proteins (IFITMs) in pharmaceutical engineering, in particular to application of IFITM 3 in preparing a medicament for treating diseases related to hepatitis B virus (HBV) infection. Eukaryotic expression vectors of IFITM 1, IFITM2 and the IFITM 3 are respectively constructed by a molecular biological method in a lab; and in vivo-in vitro tests prove that the IFITM 1, the IFITM2 and the IFITM 3 can obviously inhibit HBV replication, wherein, the IFITM 3 has the most remarkable effect. Therefore, the IFITM 3 and an encoding gene thereof are expected to become novel medicaments for treating HBV-related diseases and reducing hazard of HBV-related diseases.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
Thiourea and urea compounds and use thereof
The present invention relates to thiourea and urea compounds and use thereof. Specifically, the present invention discloses a compound having a structure represented by formula (A), or a stereoisomer,a tautomer, a pharmaceutically acceptable salt, a hydrate and a solvate thereof which can be used as an inhibitor of HBV (hepatitis B virus) replication. The invention further relates to a pharmaceutical composition comprising the compound and the use thereof in the treatment of hepatitis B.
Owner:SHANGHAI LONGWOOD PHARMA
Substituted pyrrolizine compounds and uses thereof
ActiveUS20190292187A1Organic active ingredientsOrganic chemistryCombinatorial chemistryHbv replication
This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
Owner:GILEAD SCI INC
Application of 4-hydroxy salicylanilide to preparation of medicament for preventing and treating hepatitis B
InactiveCN102920688AEnhance killing activityHigh RR enzyme inhibitory activityOrganic active ingredientsDigestive systemRibonucleotide reductaseMedicine
The invention provides new application of 4-hydroxy salicylanilide in the field of pharmacy. 4-hydroxy salicylanilide is an inhibitor of ribonucleotide reductase (RR) and inhibits the enzyme activity of RR, so that the compounding of dNTPs required by reproduction of HBV is blocked, and the aims of inhibiting reproduction of HBV, treating hepatitis and particularly treating hepatitis B are fulfilled. The 4-hydroxy salicylanilide can be used for preventing and treating the hepatitis B and has a significant application prospect.
Owner:ZHEJIANG UNIV +1
Application of oleanane triterpenoid compound in resisting hepatitis B virus
PendingCN110882255AExpression does not affectNo obvious effect on the assembly to exert anti-HBV effectOrganic active ingredientsDigestive systemPharmaceutical medicineHbv replication
The invention provides an application of an oleanane triterpenoid compound shown in a formula I, an optical isomer thereof, a solvate or a pharmaceutically acceptable salt thereof in preparation of anti-hepatitis B virus drugs. Wherein R is a hydroxyl group, a C1-10 alkylamino group, a C1-10 alkoxy group, a C1-10 alkyl group, a phenoxy group, a benzyloxy group or an imidazolyl group; the oleananetriterpenoid compound provided by the invention has a remarkable anti-HBV replication effect, and compared with clinically used drugs, the oleanane triterpenoid compound is different in structure andaction mechanism, and has a wide development prospect.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Use of sting agonists to treat hepatitis B virus infection
Owner:DREXEL UNIV
Sequence of hepatitis B virus (HBV) specific microRNA like siRNA (msiRNA) and application thereof
InactiveCN104059916AHas immunostimulatory activityInhibit expressionAntiviralsDNA/RNA fragmentationNucleotideHbv replication
The invention provides a sequence of microRNA like siRNA (msiRNA) aiming at a hepatitis B virus (HBV) S gene and a secondary structure of msiRNA. The sequence is a nucleotide sequence of msiHBs. After co-transfecting HepG2 and Huh7 cells, the msiRNA and a reporter HBV replicating plasmid pHY106+wta can inhibit expression of HBsAg and HBeAg. After transfecting the HepG2.2.15 cell, the msiHBs can also effectively inhibit the expression levels of HBsAg and HBeAg and the load of the HBV in the supernatant. Besides, the msiRNA also has the immunostimulatory activity and can activate innate immunity via a Toll like receptor pathway. Therefore, the msiRNA has double activities of inhibition of HBV gene expression as well as replication and immunostimulation and can be applied to preparation of drugs for treating HBV chronic infection.
Owner:SHIYAN TAIHE HOSPITAL
Application of niacinamide as effective component in preparation of medicine for treating hepatitis B
ActiveCN104784178AInhibit expressionInhibition of secretionOrganic active ingredientsAntiviralsNiacinamideRna expression
The invention relates to the field of drug research and development and particularly discloses application of niacinamide as an effective component in preparation of a medicine for treating hepatitis B. The experiment firstly reveals that the niacinamide is capable of inhibiting the expression level of the hepatitis B (HBV), including inhibiting the formation of the HBV replication intermediate, inhibiting the pregenome RNA expression, inhibiting the expression of a core protein and inhibiting the secretion of HBeAg and HbsAg. The niacinamide has a function of obviously treating the hepatitis B, can be used for preparing the medicine for treating the hepatitis B and has a wide application future.
Owner:CHONGQING MEDICAL UNIVERSITY
Pharmaceutical compositions for treatment or prevention of hbv infection
InactiveUS20110160252A1Suppress HBV replication was enhancedGood effectBiocideOrganic chemistryWild typeGenotype
First, the present inventors assessed the effect of the compound represented by formula (III) below on Huh-7 cells infected with HBV, and demonstrated that the compound alone had an anti-HBV effect in vitro.Formula (III)Then, the present inventors revealed that the HBV replication-suppressing effect of PEG-IFN is enhanced in chimeric mice having a human liver infected with genotype C or A HBV when PEG-IFN is used in combination with the compound represented by formula (III) above. The present inventors also revealed that the HBV replication-suppressing effect of Entecavir is enhanced in chimeric mice having a human liver infected with genotype C HBV (wild-type and Entecavir-resistant strains) when Entecavir is used in combination with the compound represented by formula (III) above. In addition, the present inventors revealed that the compound represented by formula (III) above exerts the anti-HBV effect not only against wild-type HBV strains but also against Entecavir- and / or Lamivudine-resistant HBV strains.
Owner:CHUGAI PHARMA CO LTD +1
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com